Alpha-Mannosidosis - Pipeline Review, Q2 2011

Summary

Company’s, Alpha-Mannosidosis - Pipeline Review, Q2 2011, provides an overview of the Alpha-Mannosidosis therapeutic pipeline. This report provides information on the therapeutic development for Alpha-Mannosidosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alpha-Mannosidosis. Alpha-Mannosidosis - Pipeline Review, Q2 2011 is built using data and information sourced from Company’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Company’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Alpha-Mannosidosis.
- A review of the Alpha-Mannosidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alpha-Mannosidosis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Alpha-Mannosidosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alpha-Mannosidosis pipeline depth and focus of Alpha-Mannosidosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 3
List of Figures 3
Introduction 4
Company Report Coverage 4
Alpha-Mannosidosis Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Alpha-Mannosidosis 6
Alpha-Mannosidosis Therapeutics under Development by Companies 8
Alpha-Mannosidosis Therapeutics under Investigation by Universities/Institutes 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Alpha-Mannosidosis Therapeutics - Products under Development by Companies 11
Alpha-Mannosidosis Therapeutics - Products under Investigation by Universities/Institutes 12
Companies Involved in Alpha-Mannosidosis Therapeutics Development 13
Zymenex A/S 13
Alpha-Mannosidosis - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Combination Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Drug Profiles 20
Lamazym - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Busulfan + Cyclophosphamide + Antithymocyte Globulin + Hematopoietic Stem Cell Transplantation - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Campath + Busulfan + Cyclophosphamide + Hematopoietic Stem Cell Transplantation - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Alpha-Mannosidosis Therapeutics – Drug Profile Updates 25
Alpha-Mannosidosis - Featured News 26
Jan 25, 2011: Zymenex Completes Phase I Trials For Lamazym In Alpha-Mannosidosis 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 28
Contact Us 28
Disclaimer 28

List of Tables

Number of Products Under Development for Alpha-Mannosidosis, Q2 2011 6
Products under Development for Alpha-Mannosidosis – Comparative Analysis, Q2 2011 7
Number of Products under Development by Companies, Q2 2011 8
Number of Products under Investigation by Universities/Institutes, Q2 2011 9
Comparative Analysis by Mid Clinical Stage Development, Q2 2011 10
Products under Development by Companies, Q2 2011 11
Products under Investigation by Universities/Institutes, Q2 2011 12
Zymenex A/S, 2011 13
Assessment by Monotherapy Products, Q2 2011 14
Assessment by Combination Products 15
Assessment by Stage and Route of Administration, Q2 2011 17
Assessment by Molecule Type, Q2 2011 19
Alpha-Mannosidosis Therapeutics – Drug Profile Updates 25

List of Figures

Number of Products under Development for Alpha-Mannosidosis, Q2 2011 6
Products under Development for Alpha-Mannosidosis – Comparative Analysis, Q2 2011 7
Products under Development by Companies, Q2 2011 8
Products under Investigation by Universities/Institutes, Q2 2011 9
Mid Clinical Stage Products, Q2 2011 10
Assessment by Monotherapy Products, Q2 2011 14
Assessment by Combination Products, Q2 2011 15
Assessment by Route of Administration, Q2 2011 16
Assessment by Stage and Route of Administration, Q2 2011 17
Assessment by Molecule Type, Q2 2011 18
Assessment by Stage and Molecule Type, Q2 2011 19